PL2783694T3 - Sekwencje i kompozycje peptydowe z Anopheles gambiae - Google Patents

Sekwencje i kompozycje peptydowe z Anopheles gambiae

Info

Publication number
PL2783694T3
PL2783694T3 PL14162925T PL14162925T PL2783694T3 PL 2783694 T3 PL2783694 T3 PL 2783694T3 PL 14162925 T PL14162925 T PL 14162925T PL 14162925 T PL14162925 T PL 14162925T PL 2783694 T3 PL2783694 T3 PL 2783694T3
Authority
PL
Poland
Prior art keywords
gambiase
anopheles
compositions
peptide sequences
peptide
Prior art date
Application number
PL14162925T
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Original Assignee
Peptcell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Limited filed Critical Peptcell Limited
Publication of PL2783694T3 publication Critical patent/PL2783694T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL14162925T 2007-09-13 2008-09-05 Sekwencje i kompozycje peptydowe z Anopheles gambiae PL2783694T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0717864.3A GB0717864D0 (en) 2007-09-13 2007-09-13 Peptide sequences and compositions
EP11178673A EP2407172A1 (en) 2007-09-13 2008-09-05 Peptide sequences and compositions
EP08803793A EP2182972A2 (en) 2007-09-13 2008-09-05 Peptide sequences and compositions
EP14162925.3A EP2783694B1 (en) 2007-09-13 2008-09-05 Peptide sequences and compositions from Anopheles gambiase

Publications (1)

Publication Number Publication Date
PL2783694T3 true PL2783694T3 (pl) 2018-10-31

Family

ID=38658898

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14162925T PL2783694T3 (pl) 2007-09-13 2008-09-05 Sekwencje i kompozycje peptydowe z Anopheles gambiae

Country Status (25)

Country Link
US (2) US8986703B2 (pl)
EP (4) EP2567706A3 (pl)
JP (3) JP2010539127A (pl)
CN (1) CN101815526B (pl)
AR (1) AR068428A1 (pl)
AU (1) AU2008297213B2 (pl)
BR (1) BRPI0816330A2 (pl)
CA (1) CA2699467A1 (pl)
CL (1) CL2008002727A1 (pl)
CO (1) CO6270336A2 (pl)
DK (1) DK2783694T3 (pl)
ES (1) ES2670859T3 (pl)
GB (1) GB0717864D0 (pl)
HU (1) HUE038953T2 (pl)
MX (1) MX2010002025A (pl)
NO (1) NO2783694T3 (pl)
PE (1) PE20090682A1 (pl)
PL (1) PL2783694T3 (pl)
PT (1) PT2783694T (pl)
RU (1) RU2466737C2 (pl)
SG (1) SG187401A1 (pl)
TR (1) TR201807414T4 (pl)
TW (1) TWI548646B (pl)
WO (1) WO2009034041A2 (pl)
ZA (1) ZA201000914B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015445A1 (en) * 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
EP2191849B1 (en) * 2007-09-26 2018-08-01 National Cerebral and Cardiovascular Center Drug for suppressing pathogen occurring in vivo
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
FR2955393B1 (fr) * 2010-01-18 2015-12-11 Inst Rech Developpement Ird Methode pour evaluer l'efficacite de strategies de lutte anti-vectorielle dans le controle du paludisme et des arboviroses
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
MX2015011257A (es) * 2013-03-08 2015-11-16 Taiho Pharmaceutical Co Ltd Peptido novedoso que tiene 5 epitopos de linfocitos t citotoxicos enlazados.
US10898555B2 (en) * 2013-07-02 2021-01-26 Japanese Foundation For Cancer Research Cellular immunity inducing vaccine
JP6211093B2 (ja) * 2013-10-21 2017-10-11 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
CN104356216B (zh) * 2014-10-09 2017-03-01 昆明医科大学 版纳绳蚋防御肽SibaDef及其基因和应用
US11452769B2 (en) * 2015-02-02 2022-09-27 Yale University Mosquito saliva protein malaria vaccine
US9913903B2 (en) * 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
JP6893765B2 (ja) * 2016-07-15 2021-06-23 森山　雅美 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤
CN107236028B (zh) * 2017-07-05 2020-12-04 贵州医科大学 白纹伊蚊唾液34K2重组蛋白在DENV2感染HaCaT细胞中的应用
TW202333769A (zh) 2018-06-29 2023-09-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
EP4013410A4 (en) * 2019-08-13 2023-10-25 Tata Consultancy Services Limited SYSTEM AND METHOD FOR ASSESSING THE RISK OF COLORECTAL CANCER
US20220328193A1 (en) * 2019-08-13 2022-10-13 Tata Consultancy Services Limited System and method for assessing the risk of prediabetes
KR102615021B1 (ko) * 2021-10-14 2023-12-20 주식회사 메디트 3차원 스캐너의 스캔 이미지 정렬 방법, 장치 및 명령을 기록한 기록매체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004714A (es) * 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.

Also Published As

Publication number Publication date
US8986703B2 (en) 2015-03-24
EP2567706A2 (en) 2013-03-13
EP2783694A2 (en) 2014-10-01
TW200920398A (en) 2009-05-16
SG187401A1 (en) 2013-02-28
EP2783694B1 (en) 2018-02-28
USRE47222E1 (en) 2019-02-05
CO6270336A2 (es) 2011-04-20
GB0717864D0 (en) 2007-10-24
AU2008297213B2 (en) 2013-01-24
JP2016135767A (ja) 2016-07-28
EP2182972A2 (en) 2010-05-12
WO2009034041A3 (en) 2009-06-25
TR201807414T4 (tr) 2018-06-21
AU2008297213A1 (en) 2009-03-19
CL2008002727A1 (es) 2009-03-06
JP6227018B2 (ja) 2017-11-08
ZA201000914B (en) 2011-04-28
DK2783694T3 (en) 2018-06-14
ES2670859T3 (es) 2018-06-01
EP2783694A3 (en) 2015-01-07
CN101815526B (zh) 2014-03-19
WO2009034041A2 (en) 2009-03-19
PE20090682A1 (es) 2009-06-22
NO2783694T3 (pl) 2018-07-28
JP2010539127A (ja) 2010-12-16
AR068428A1 (es) 2009-11-18
TWI548646B (zh) 2016-09-11
JP2013240330A (ja) 2013-12-05
CA2699467A1 (en) 2009-03-19
EP2567706A3 (en) 2013-06-12
RU2010114597A (ru) 2011-10-20
HUE038953T2 (hu) 2018-12-28
RU2466737C2 (ru) 2012-11-20
US20100297187A1 (en) 2010-11-25
PT2783694T (pt) 2018-06-07
CN101815526A (zh) 2010-08-25
EP2407172A1 (en) 2012-01-18
MX2010002025A (es) 2010-03-15
JP5981883B2 (ja) 2016-08-31
BRPI0816330A2 (pt) 2015-04-14

Similar Documents

Publication Publication Date Title
HUE038953T2 (hu) Peptid szekvenciák és készítmények anopheles gambiae-fajból
IL251867A0 (en) Peptide sequences and compounds
LT2178549T (lt) Antimikrobinis peptidas ir jo kompozicijos
HUS1700016I1 (hu) Liraglutidot és degludeket tartalmazó stabil gyógyszerészeti készítmények
IL204183A (en) Preparations and Methods for Using Froisslet Peptides and Their Analogs
IL196591A0 (en) Cyclosporin compositions
EP2017283A4 (en) Peptides
PL2392587T3 (pl) Sekwencje i kompozycje peptydów
GB0604187D0 (en) Peptide and uses thereof
GB0618748D0 (en) Peptide
EP2091959A4 (en) IMPROVED PEPTIDE COMPOSITION
GB0708529D0 (en) Peptide standards
ZA200806753B (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions
GB0605774D0 (en) Peptide
HK1143743A (en) Peptide sequences and compositions
AU2007903495A0 (en) Novel Peptide Compositions and Uses Thereof
AU2007901197A0 (en) Novel peptide compositions and uses thereof
ZA200900448B (en) Cyclosporin compositions